For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Entera Bio Ltd. (ENTX) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question. Entera Bio Ltd. is one of 1017 individual stocks in the Medical sector. Collectively, these companies sit at #5 in the Zacks Sector Rank. The Zacks Sector Rank considers 1 ...

Core Insights - Entera Bio Ltd. is focused on developing orally delivered peptides and small therapeutic proteins to address significant unmet medical needs in the healthcare sector [2] Group 1: Company Overview - Entera is a clinical stage company with a proprietary technology platform (N-Tab™) aimed at transforming the standard of care through oral peptide or protein replacement therapies [2] - The company has five differentiated, first-in-class oral peptide programs expected to enter clinical trials (Phase 1 to Phase 3) by 2025 [2] - The most advanced product candidate, EB613, is being developed as the first oral, osteoanabolic once-daily tablet treatment for post-menopausal women with low bone mineral density (BMD) and high-risk osteoporosis [2] Group 2: Clinical Development - A Phase 2 study of EB613 tablets (n=161) met both primary (PD/bone turnover biomarker) and secondary endpoints (BMD) [2] - Entera is preparing to initiate a Phase 3 registrational study for EB613, with FDA qualification of a quantitative BMD endpoint expected by January 2025 [2] - The EB612 program is being developed as the first oral PTH(1-34) tablet peptide replacement therapy for hypoparathyroidism [2] Group 3: Additional Product Development - Entera is also developing the first oral oxyntomodulin, a dual-targeted GLP1/glucagon peptide, in tablet form for obesity treatment [2] - The first oral GLP-2 peptide tablet is being developed as an injection-free alternative for patients with rare malabsorption conditions, in collaboration with OPKO Health [2] Group 4: Upcoming Conferences - Management will participate in several upcoming investor and scientific conferences, including: - H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024 [1] - American Society for Bone and Mineral Research 2024 Annual Meeting on September 28, 2024 [1] - 7th Annual Evercore ISI HealthCONx Conference on December 4, 2024 [1]

Core Viewpoint - Entera Bio Ltd. (ENTX) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive trend in earnings estimates which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Performance - The Zacks rating system is based on changes in earnings estimates, which are closely correlated with stock price movements, particularly due to institutional investors adjusting their valuations based on these estimates [4][6]. - For the fiscal year ending December 2024, Entera Bio is expected to earn -$0.23 per share, reflecting a 25.8% change from the previous year's reported number [8]. Analyst Sentiment and Market Position - Analysts have been consistently raising their earnings estimates for Entera Bio, with the Zacks Consensus Estimate increasing by 8% over the past three months [8]. - The upgrade to Zacks Rank 2 places Entera Bio in the top 20% of Zacks-covered stocks, suggesting a strong potential for market-beating returns in the near term [10].

Core Insights - Entera Bio Ltd. reported strong execution and key milestones in its N-Tab™ oral peptide programs, with a significant upcoming FDA ruling on the ASBMR-FNIH SABRE regulatory endpoint for osteoporosis drugs, which is seen as a major catalyst for its product EB613 [2][3] Financial Performance - As of June 30, 2024, Entera had cash and cash equivalents of $9.1 million, sufficient to meet projected operating requirements into Q3 2025 [6] - Research and development expenses for Q2 2024 were $1.1 million, a decrease from $1.2 million in Q2 2023, primarily due to reduced clinical expenses [7] - General and administrative expenses remained stable at $1.1 million for both Q2 2024 and Q2 2023 [8] - Total operating expenses for Q2 2024 were $2.2 million, down from $2.3 million in Q2 2023, with a net loss of $2.1 million or $0.06 per share, compared to a net loss of $2.3 million or $0.08 per share in the previous year [8][15] Product Development Updates - EB613, the first oral PTH(1-34) daily osteoanabolic tablet for osteoporosis, is preparing for a pivotal study targeting a wider population, with a Phase 2 study already meeting its primary and secondary endpoints [3][9] - EB612, focused on hypoparathyroidism, is moving towards Phase 2 development following positive Phase 1 clinical data presented in June 2024 [4] - Entera is also developing the first oral GLP-2 peptide tablets for short bowel syndrome and oral oxyntomodulin for obesity, with pharmacological data expected in the second half of 2024 [5][9]

Core Insights - Entera Bio Ltd. is advancing its investigational agent EB613, an oral anabolic therapy for post-menopausal women with high-risk osteoporosis, with new pharmacological data to be presented at the ASBMR 2024 Annual Meeting [1][2][3] Company Overview - Entera Bio is focused on developing orally delivered peptides and therapeutic proteins, leveraging its proprietary N-Tab™ technology platform [4] - The company has a pipeline that includes five differentiated oral peptide programs expected to enter clinical trials by 2025 [4] Product Development - EB613 is designed as the first once-daily oral PTH(1-34) mini tablet therapy for post-menopausal women, addressing a significant unmet medical need in osteoporosis treatment [2][3] - Approximately 200 million women globally are affected by post-menopausal osteoporosis, which poses a serious health risk [2] - A Phase 2 study of EB613 met primary and secondary endpoints, and the company is preparing for a Phase 3 registrational study pending FDA qualification of bone mineral density as a surrogate endpoint [4] Upcoming Events - New comparative pharmacological data for EB613 will be presented at the ASBMR 2024 Annual Meeting, scheduled for September 27-30, 2024, in Toronto, Canada [1][4] - The SABRE project update will also be presented, highlighting the FDA's communication regarding bone mineral density as a regulatory endpoint [3][4]

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Entera Bio Ltd. (ENTX) been one of those stocks this year? A quick glance at the company's yearto-date performance in comparison to the rest of the Medical sector should help us answer this question. Entera Bio Ltd. is one of 1046 companies in the Medical group. The Medical group currently sits at #8 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuri ...

Group 1 - Entera Bio Ltd. (ENTX) has significantly outperformed the Medical sector with a year-to-date return of 336.7%, compared to an average gain of 5.6% for Medical stocks [4] - The Zacks Rank for Entera Bio Ltd. is currently 2 (Buy), indicating strong analyst sentiment and an improving earnings outlook, with a 66.7% increase in the consensus estimate for full-year earnings over the past quarter [3] - Entera Bio Ltd. is part of the Medical - Biomedical and Genetics industry, which includes 506 companies and currently ranks 92 in the Zacks Industry Rank, while the average performance of this group has been a loss of 2.4% this year [5] Group 2 - Assembly Biosciences (ASMB) is another Medical stock that has outperformed the sector with a year-to-date return of 48.4% and also holds a Zacks Rank of 2 (Buy) [4][5] - The consensus EPS estimate for Assembly Biosciences has increased by 14.3% over the past three months, reflecting positive analyst sentiment [5] - The Medical - Generic Drugs industry, to which Assembly Biosciences belongs, has seen a year-to-date increase of 11.1% and currently ranks 52 [6]

JERUSALEM, May 13, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), ("Entera" or the "Company") a leader in the development of orally delivered peptides and small therapeutic proteins, today announced that it has been selected to present data for its investigational program EB612 at the Endocrine Society ENDO 2024 Annual Meeting which will be held on June 1-4, 2024 in Boston, Massachusetts. The EB612 program is being developed by Entera to provide the first oral PTH(1-34) tablet peptide replacement t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) ...

Exhibit 99.1 Entera Bio Reports Q1 2024 Financial Results and Provides Business Updates JERUSALEM – May 10th, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), ("Entera" or the "Company") a leader in the development of orally delivered peptides and small therapeutic proteins, today reported financial results and key business updates for the quarter ended March 31, 2024. "Entera is off to a strong start in 2024 thanks to the growth strategy we implemented in 2023, expanding our N-Tab™ therapeutic pipe ...